HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolfe, W. G. Articles by Duhaylongsod, F. G. Search for Related Content PubMed PubMed Citation Articles by Wolfe, W. G. Articles by Duhaylongsod, F. G.

The Journal of Thoracic and Cardiovascular Surgery, Vol 105, 749-755, Copyright © 1993 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Survival of patients with carcinoma of the esophagus treated with combined-modality therapy

WG Wolfe, AL Vaughn, HF Seigler, JW Hathorn, KA Leopold and FG Duhaylongsod
Department of Surgery, Duke University Medical Center, Durham, NC 27710.

Since 1985, 229 cases of carcinoma of the esophagus have been considered for entry into a protocol with the use of preoperative chemotherapy and radiation therapy followed by surgical intervention as the primary element of treatment. One hundred sixty-five patients (93 with adenocarcinoma and 72 with squamous cell carcinoma) had esophagogastrectomy. The 5-year survival of the protocol patients who underwent resection was 25% for both groups--squamous cell carcinoma and adenocarcinoma. Of the protocol patients with squamous cell carcinoma who underwent resection, 40% had a sterilized specimen, whereas of those with adenocarcinoma, 20% had a sterilized specimen. If the patient had a sterilized specimen, the 5-year survival was approximately 60% for adenocarcinoma and 40% for squamous cell carcinoma. Those patients with adenocarcinoma and Barrett's esophagus had a 5-year survival of 55%. Of the patients who underwent only esophagectomy and esophagogastrectomy and had not been entered into the protocol, none lived beyond 3 years. The operative mortality rate for those who had esophagogastrectomy was 5%. Sixty-four patients completed the radiation therapy and chemotherapy but did not undergo surgical procedures because of progressive disease or refusal. Of those patients who completed chemotherapy and radiation therapy without surgical intervention, 5-year survival was 18% in patients with squamous cell carcinoma, whereas no patients with adenocarcinoma survived beyond 3 years. The finding of a sterilized specimen after esophagectomy is a favorable prognostic factor in patients with adenocarcinoma or squamous cell carcinoma. The finding that patients with Barrett's esophagus and adenocarcinoma have an improved chance for survival is perhaps related to an earlier diagnosis. It is clear that some patients with squamous cell carcinoma who did not undergo surgical procedures did have a sterilized specimen, because the survival in this group approached 20% at 5 years.

This article has been cited by other articles:

				M. Tachibana, S. Kinugasa, N. Hirahara, and H. Yoshimura Lymph node classification of esophageal squamous cell carcinoma and adenocarcinoma. Eur. J. Cardiothorac. Surg., August 1, 2008; 34(2): 427 - 431. [Abstract] [Full Text] [PDF]

				L. Kleinberg and A. A. Forastiere Chemoradiation in the Management of Esophageal Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4110 - 4117. [Abstract] [Full Text] [PDF]

				M.-B. Moore Joshi, Y. Shirota, K. D. Danenberg, D. H. Conlon, D. S. Salonga, J. E. Herndon II, P. V. Danenberg, and D. H. Harpole Jr. High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer Clin. Cancer Res., March 15, 2005; 11(6): 2215 - 2221. [Abstract] [Full Text] [PDF]

				L. Kostakoglu and S. J. Goldsmith PET in the Assessment of Therapy Response in Patients with Carcinoma of the Head and Neck and of the Esophagus J. Nucl. Med., January 1, 2004; 45(1): 56 - 68. [Abstract] [Full Text] [PDF]

				M. K. Gibson, S. C. Abraham, T.-T. Wu, B. Burtness, R. F. Heitmiller, E. Heath, and A. Forastiere Epidermal Growth Factor Receptor, p53 Mutation, and Pathological Response Predict Survival in Patients with Locally Advanced Esophageal Cancer Treated with Preoperative Chemoradiotherapy Clin. Cancer Res., December 15, 2003; 9(17): 6461 - 6468. [Abstract] [Full Text] [PDF]

				J. M. Inadomi, R. Sampliner, J. Lagergren, D. Lieberman, A M. Fendrick, and N. Vakil Screening and Surveillance for Barrett Esophagus in High-Risk Groups: A Cost-Utility Analysis Ann Intern Med, February 4, 2003; 138(3): 176 - 186. [Abstract] [Full Text] [PDF]

				B Dunne, J V Reynolds, E Mulligan, A Kelly, and M Griffin A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy J. Clin. Pathol., November 1, 2001; 54(11): 841 - 845. [Abstract] [Full Text] [PDF]

				D. H. Harpole Jr., M.-B. Moore, J. E. Herndon II, T. Aloia, T. A. D'Amico, T. Sporn, A. Parr, I. Linoila, and C. Allegra The Prognostic Value of Molecular Marker Analysis in Patients Treated with Trimodality Therapy for Esophageal Cancer Clin. Cancer Res., March 1, 2001; 7(3): 562 - 569. [Abstract] [Full Text]

				S. J. Hoff, J. L. Sawyers, C. D. Blanke, H. Choy, and J. R. Stewart Prognosis of Adenocarcinoma Arising in Barrett's Esophagus Ann. Thorac. Surg., January 1, 1998; 65(1): 176 - 181. [Abstract] [Full Text] [PDF]

				C. D. Wright, J. C. Wain, T. J. Lynch, N. C. Choi, M. L. Grossbard, R. W. Carey, A. C. Moncure, H. C. Grillo, and D. J. Mathisen INDUCTION THERAPY FOR ESOPHAGEAL CANCER WITH PACLITAXEL AND HYPERFRACTIONATED RADIOTHERAPY: A PHASE I AND II STUDY J. Thorac. Cardiovasc. Surg., November 1, 1997; 114(5): 811 - 816. [Abstract] [Full Text]

				D. R. Jones, F. C. Detterbeck, T. M. Egan, L. A. Parker Jr, S. A. Bernard, and J. E. Tepper Induction Chemoradiotherapy Followed by Esophagectomy in Patients With Carcinoma of the Esophagus Ann. Thorac. Surg., July 1, 1997; 64(1): 185 - 192. [Abstract] [Full Text]

				R. A. Badwe, J. S. Vaidya, M. S. Bhansali, P. Gaffney, E. M. Funk, J. Witte, T. N. Walsh, A. Kelly, and T. P.J. Hennessy Multimodal Therapy for Esophageal Adenocarcinoma N. Engl. J. Med., January 30, 1997; 336(5): 374 - 376. [Full Text]

				T. N. Walsh, N. Noonan, D. Hollywood, A. Kelly, N. Keeling, and T. P.J. Hennessy A Comparison of Multimodal Therapy and Surgery for Esophageal Adenocarcinoma N. Engl. J. Med., August 15, 1996; 335(7): 462 - 467. [Abstract] [Full Text] [PDF]

				S. G. Swisher, E. C. Holmes, K. K. Hunt, J. E. Doty, M. J. Zinner, and D. W. McFadden The Role of Neoadjuvant Therapy in Surgically Resectable Esophageal Cancer Arch Surg, August 1, 1996; 131(8): 819 - 825. [Abstract] [PDF]